COGNITION THERAPEUTICS INC (Stock Symbol: CGTX)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
The organization employs approximately 29 professionals worldwide
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $158 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for COGNITION THERAPEUTICS INC stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
COGNITION THERAPEUTICS INC strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
COGNITION THERAPEUTICS INC (CGTX) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for COGNITION THERAPEUTICS INC stock analysis.
Loading fundamental data...
Loading COGNITION THERAPEUTICS INC comprehensive fundamental analysis and insider trading data...
Deep dive into COGNITION THERAPEUTICS INC's financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if COGNITION THERAPEUTICS INC stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For COGNITION THERAPEUTICS INC: With a P/E ratio of -0,47, the market sees the stock as potentially undervalued.
P/E Ratio-0,47x
P/B Ratio22,46x
Market Cap$158M
EPS$-0,66
Book Value/Share$0,11
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently COGNITION THERAPEUTICS INC converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For COGNITION THERAPEUTICS INC:
ROA-51,0%
Understanding Financial Health Metrics
What these metrics mean: These ratios assess COGNITION THERAPEUTICS INC's ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For COGNITION THERAPEUTICS INC: A current ratio of 7,38 indicates strong liquidity.
Current Ratio7,38x
Quick Ratio7,10x
D/E Ratio0,01x
Financial Leverage1,20x
Interest Coverage-41,9x
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal COGNITION THERAPEUTICS INC's ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For COGNITION THERAPEUTICS INC: Free cash flow of $-6M indicates cash challenges that need attention.
Operating Cash Flow$-6M
Free Cash Flow$-6M
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively COGNITION THERAPEUTICS INC uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For COGNITION THERAPEUTICS INC:
Understanding Financial Statement Data
What these metrics mean: Key figures from COGNITION THERAPEUTICS INC's income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study has ...
Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced ...
Investing.com -- Cognition Therapeutics Inc. (NASDAQ:CGTX) stock fell 17% after the clinical-stage company announced a $30 million registered direct offering of common stock.
Cognition Therapeutics discussed zervimesine’s Phase 2 results and future Phase 3 plans with the FDA for Alzheimer’s treatment. Quiver AI Summary Cognition Therapeutics, Inc. announced that on ...
Cognition Therapeutics, Inc. (NASDAQ:CGTX – Get Free Report) has received an average rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. One ...
About Cognition Therapeutics, Inc. Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age ...
Cognition Therapeutics announces Dr. Mary Hamby's workshop on precision medicine for Alzheimer's at the Neuroimmunology Summit, featuring SHINE study results.
About Cognition Therapeutics, Inc. Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age ...
Cognition Therapeutics Inc. said it is moving to the next stage of clinical testing with oral, small-molecule candidate CT-1812, despite phase II efficacy results falling short of statistical ...
Comparative analysis of COGNITION THERAPEUTICS INC against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
How accurate are COGNITION THERAPEUTICS INC stock predictions?
Our AI model demonstrates -1% historical accuracy for CGTX predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence COGNITION THERAPEUTICS INC stock price forecasts?
Is COGNITION THERAPEUTICS INC a good investment in 2025?
Based on our AI analysis, COGNITION THERAPEUTICS INC shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are COGNITION THERAPEUTICS INC forecasts updated?
COGNITION THERAPEUTICS INC stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced COGNITION THERAPEUTICS INC Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for COGNITION THERAPEUTICS INC stock.
